Navigation Links
Global Pharm Holdings Group Announces First Quarter 2011 Financial Results
Date:5/16/2011

ng as Vice President in charge of operations of Global Pharm for a term of three years, effective May 1, 2011, thereby increasing the number of Global Pharm executive officers from three to four.

On April 25, 2011, the Company suspended its flower tea bags and sales operations. The Company's decision was based on the intentions of the local government of Bozhou, in conjunction with another pharmaceutical company, to expand the industry development park in Bozhou, that will utilize the site where Xuelingxian is currently located. The factory buildings and relevant land on which Xuelingxian is situated will be expropriated and Xuelingxian will be required to relocate to a new commercial address. The Company is currently evaluating potential new locations and is conducting market research on the flower tea bags market. The management will decide to either reopen the flower tea bags business in a new location or permanently close it after completing its market research, which expected to be completed in mid-2011.

On April 21, 2011, the Company obtained a business license for its newly established joint venture, Shandong Sino-Green TCM Tech Development Co., Ltd. ("Shandong Sino-Green") in Jinan City, Shandong Province. The joint venture was established between Shandong Global Pharm and Jinan Linong TCM Plantation Co., Ltd. ("Jinan Linong"), a PRC company, in Mashan Town of Changqing District of Jinan City, Shandong province. The registered capital of Shandong Sino-Green is RMB 10 million ($1.5 million). Shandong Global Pharm will invest RMB 9.7 million ($1.5 million) and Jinan Linong will invest RMB 0.3 million ($0.1 million), which reflects 97 percent and 3 percent of the ownership of Shandong Sino-Green, respectively. On April 20, 2011, the Company paid RMB 9.7 million (approximately $1.5 million) registered capital.

On April 6, 2011, the Company obtained the business license for its newly established joint venture, Anhui Sino-Green TCM Tech Deve
'/>"/>

SOURCE Global Pharm Holdings Group, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
2. Dr. Roger Kenneth Hershline PhD MD, CEO of Global Humanceuticals, Inc. Donates New HIV Drug
3. Directors Forum: PEPFAR and the Global AIDS Response
4. Alfacell Corporation to Present at UBS Global Life Sciences Conference
5. Baxa Corporation Extends Global Reach With New Distribution Agreements in Colombia and the Dominican Republic
6. Global HIV Vaccine Enterprise Names Alan Bernstein as Inaugural Executive Director, Opens New Secretariat
7. President Clinton Highlights MWW Group at the 2007 Clinton Global Initiative for its Stop Neglected Tropical Disease Campaign
8. Hillary Clinton Pledges Bold Approach to Stopping HIV/AIDS & Global Poverty
9. IBA and Elekta Initiate Global Particle Therapy Program at ASTRO
10. Dr. Rajeev Venkayya Joins Gates Foundation as Director of Global Health Delivery
11. BioNumerik Commences Global Phase III Ovarian Cancer Trial on Novel Anticancer Drug Candidate Known as Karenitecin(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... --  Nektar Therapeutics (Nasdaq: NKTR ) today ... study for NKTR-181, a first-in-class, opioid analgesic molecule ... slow rate of entry is designed to reduce the euphoria ... current opioid analgesics. 1 In the study data being ... in "drug liking" and "feeling high" scores and had highly ...
(Date:6/19/2013)... 2013 BD Biosciences, a segment of BD (Becton, ... global medical technology company, today announced the launch of the ... its line of high-performance research flow cytometers. ... with the most compact footprint in its class at just ... of 30" (76.2 cm). Recognizing that space is a valuable ...
(Date:6/19/2013)... ZIONA, Israel , June ... announced that results from a phase I study in ... in advanced Parkinson,s patients, of ND0612, were presented at ... Disorders. ND0612 is a proprietary levodopa/carbidopa liquid drug formula ... delivery patch that would maintain constant levodopa plasma concentrations. ...
Breaking Medicine Technology:Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 2Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 3Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 4Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 5Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 6Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 7Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 8Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 9New BD Biosciences Flow Cytometry Cell Analyzer Enables Complex Multicolor Experiments in Disease Research 2NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 2NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 3NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 4NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 5NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 6
... treated with,Exforge achieved recommended blood pressure goals[1] , ... observed in patients taking Exforge over,reductions seen with previous ... blood pressure not,at treatment target levels[2] and most require ... , BASEL, Switzerland, May 21, 2007 ...
... by FDA for long-term maintenance,treatment of COPD ... improved lung function,comparable to dry powder formoterol, ... profile --, NAPA, Calif., May 20, 2007 ... of the American Thoracic Society (ATS),demonstrate that ...
Cached Medicine Technology:Exforge Helps Vast Majority of Patients Effectively Control Their,Blood Pressure After Failing on Other Medicines, According to New,Clinical Data 2Exforge Helps Vast Majority of Patients Effectively Control Their,Blood Pressure After Failing on Other Medicines, According to New,Clinical Data 3Exforge Helps Vast Majority of Patients Effectively Control Their,Blood Pressure After Failing on Other Medicines, According to New,Clinical Data 4Exforge Helps Vast Majority of Patients Effectively Control Their,Blood Pressure After Failing on Other Medicines, According to New,Clinical Data 5Exforge Helps Vast Majority of Patients Effectively Control Their,Blood Pressure After Failing on Other Medicines, According to New,Clinical Data 6Exforge Helps Vast Majority of Patients Effectively Control Their,Blood Pressure After Failing on Other Medicines, According to New,Clinical Data 7Exforge Helps Vast Majority of Patients Effectively Control Their,Blood Pressure After Failing on Other Medicines, According to New,Clinical Data 8Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 2Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 3Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 4Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 5Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 6Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 7
(Date:6/19/2013)... Chrysler made news recently when it refused ... million Jeeps. The Jeep models in question are the 1993-2004 ... to the NHTSA are vulnerable to fire and explosion in ... are rear-mounted and have been alleged to catch fire or ... Cherokee with 32 rear-end crashes, which resulted in 44 deaths ...
(Date:6/19/2013)... CA (PRWEB) June 19, 2013 According to ... for Surviving Weekend Sunburn,” it is not uncommon for a ... the summer months. A person is likely to forget to ... , which is both dry and itchy. When this occurs, ... (Go to goo.gl/gDyjP). , “Most people do not realize that ...
(Date:6/19/2013)... a study published in the June 19 online edition ... led by researchers from the University of California, San ... events that take place when cardiac regeneration occurs in ... evidence that various cell lines in the heart are ... types, than previously thought. , More importantly, the research ...
(Date:6/19/2013)... This news release is available in Spanish . ... the field of neglected diseases, it goes by the name ... health research was devoted to conditions that accounted for 90 ... counteract this imbalance that the Drugs for Neglected Diseases initiative ... anniversary year, the organization has been granted the BBVA Foundation ...
(Date:6/19/2013)... California (PRWEB) June 19, 2013 Effective Environmental ... launch of new websites. These online links are devoted to ... Septic Tank cleaner, Organic Odor Control Mold Magician and others. ... for fish and animals in the water as well as ... and sludge buildup that can accumulate at the bottom of ...
Breaking Medicine News(10 mins):Health News:Zinda & Davis PLLC: Why the Chrysler Recall Refusal Matters And May Set a Dangerous Precedent 2Health News:Zinda & Davis PLLC: Why the Chrysler Recall Refusal Matters And May Set a Dangerous Precedent 3Health News:Skin Care – How to treat Sunburn 2Health News:Fate of the heart: Researchers track cellular events leading to cardiac regeneration 2Health News:DNDi receives the BBVA Foundation Frontiers of Knowledge Award in Development Cooperation 2Health News:DNDi receives the BBVA Foundation Frontiers of Knowledge Award in Development Cooperation 3Health News:DNDi receives the BBVA Foundation Frontiers of Knowledge Award in Development Cooperation 4Health News:DNDi receives the BBVA Foundation Frontiers of Knowledge Award in Development Cooperation 5Health News:Effective Environmental Services Launch New Websites to Serve Customers 2
... A study by Henry Ford Hospital shows a direct association between ... shows that in most cases the rupture heals on its own ... "In the past, many otolaryngologists have wondered if surgery is really ... show that 97 percent of cases healed on their own within ...
... (HealthDay News) -- Memory in monkeys and humans is more ... with rhesus monkeys showed that, like people, they have both ... something when you see it. Recall is the ability to ... April 28 in the journal Current Biology . ...
... Behen HealthDay Reporter , THURSDAY, April 28 ... expand research and improve understanding of cancer among minority ... the President,s Cancer Panel. While minorities currently account ... expected to become the collective majority by the year ...
... Researchers have developed an effective technique that uses gene ... in cell culture, which could eventually serve as a treatment ... study published in Blood , the ... prevents neutrophils, a type of white blood cell of the ...
... in Germany compared with the rest of Europe. Extensive folic ... 85-100% of cases, Wolfgang Herrmann and Rima Obeid argue in ... Int 2011; 108[15]; 249-54). A woman,s folic acid intake ... not develop the neural tube defect commonly known as spina ...
... The largest study of its type has found that neither ... metformin, successfully reduced liver enzymes in nonalcoholic fatty liver disease ... the April 27, 2011 issue of Journal of the ... patients with a severe type of fatty liver disease, a ...
Cached Medicine News:Health News:Study: Cotton swabs prove problematic for ear health 2Health News:'Urgent Need' for Research on Cancer Among Minorities: U.S. Report 2Health News:'Urgent Need' for Research on Cancer Among Minorities: U.S. Report 3Health News:New gene therapy technique on iPS cells holds promise in treating immune system disease 2Health News:New gene therapy technique on iPS cells holds promise in treating immune system disease 3Health News:JAMA study reports on fatty liver disease in children and teens 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: